Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Tumorigenicity Potential Assessment of iPSC-Derived Cell Products in Immunodeficient Mice

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Tumorigenicity Potential Assessment of iPSC-Derived Cell Products in Immunodeficient Mice

Tumorigenicity Assessment for iPSC-Derived Cell Therapies

CELL & GENE | RNA | BIOLOGICS

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Executive Summary

The technical framework for assessing the tumorigenicity potential of induced pluripotent stem cell (iPSC)-derived cell therapy products is a core component of any preclinical program. We detail the regulatory rationale for these studies, the use of immunodeficient models to isolate and evaluate the risk of teratoma formation or malignant transformation, and the study design parameters. Key endpoints include clinical observations, terminal gross necropsy, and comprehensive GxP-compliant histology of implantation sites and key organs. These studies are a required component of the safety package for any iPSC-based therapeutic advancing toward an Investigational New Drug (IND) application.

Frequently Asked Questions: iPSC Tumorigenicity

What is the primary purpose of a tumorigenicity study for iPSC-derived products?

The primary objective is to assess the risk of tumor or teratoma formation from residual undifferentiated pluripotent stem cells within the final cell therapy product. It is a foundational safety study required by regulatory agencies to ensure the product does not cause neoplastic growth after administration.

Why are immunodeficient models required for these assessments?

Immunodeficient models (e.g., NOD/SCID, NSG) are necessary because they lack a functional adaptive immune system. This prevents the host from rejecting the human-derived iPSC product, allowing any residual pluripotent cells to survive, proliferate, and reveal their tumorigenic potential over the course of the study.

What are the key endpoints in a typical iPSC tumorigenicity study?

Key endpoints include:

  • In-life monitoring for palpable mass formation at the administration site.

  • Scheduled body weight measurements and clinical observations.

  • Terminal gross necropsy to identify and measure any abnormal tissue masses.

  • Comprehensive GxP histology of the administration site and a standard set of tissues to identify and characterize neoplastic or teratoma-like structures.

How long is the in-life phase for these studies?

The in-life observation period is typically 6 months, though the exact duration can be adapted based on the specific cell product, its proliferation kinetics, and discussions with regulatory bodies.

Defining the Regulatory Requirement: Assessing Malignant Transformation

The clinical promise of iPSC-derived cell therapies is linked directly to their pluripotency. However, this same biological characteristic presents a distinct safety challenge: the potential for residual undifferentiated cells in the final product to form teratomas or other tumors in vivo. Regulatory bodies mandate robust preclinical evaluation to mitigate this risk.

A tumorigenicity study is designed to provide definitive data on whether the manufacturing process effectively eliminates pluripotent cells and if the final, differentiated cell product is safe for clinical administration. This assessment forms a core part of the IND-enabling data package, with an average development timeline of 18-24 months from program initiation to submission.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

The Role of Immunodeficient Models in Isolating Therapeutic Activity

The use of immunodeficient models to isolate the intrinsic biological activity of a therapeutic agent is a well-established preclinical strategy. For instance, studies have leveraged these models to evaluate AAV-mediated antibody expression without confounding host immune responses (PMID: 25209558) or to dissect the primary immunogenicity of novel vector platforms (PMID: 17715240).

A similar principle applies to cell therapies. These models are indispensable for assessing tumorigenic potential absent of host-mediated cell rejection. This allows for an unambiguous evaluation of the cell product’s inherent capacity for neoplastic growth, providing the clear, interpretable data required for regulatory review.

Watch the full-length video on DIVERSIFYING THE VALUE CHAIN

Study Design and Execution for IND-Enabling Data

A robust tumorigenicity study requires meticulous design and execution within a GxP framework. Our >100,000 sq ft facility is equipped to manage these long-term studies with precision.

Study Phase Key Activities & Endpoints Compliance Standard
Dosing & In-Life Administration of test article (e.g., subcutaneous, intramuscular). Weekly clinical observations, body weights, and palpation for mass formation. GxP, IACUC
Terminal Procedures Full gross necropsy at study termination (typically 6 months). Collection and measurement of any observed masses. GxP
Histology & Analysis Fixation of administration site and key tissues (e.g., lung, liver, spleen, brain). Board-certified pathologist review of H&E-stained slides. GxP
Reporting Comprehensive final report detailing all methods, observations, macroscopic findings, and microscopic diagnoses. GxP

Since the Franklin Biolabs brand launch in 2024, programs leveraging our preclinical platforms have maintained a 100% IND success rate, building on a legacy of scientific excellence dating back to 2019.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

Animal Welfare and GxP Compliance

All in vivo studies are conducted in strict adherence to animal welfare regulations.

  • Accreditation: Through our strategic partners, including the Bioculture Group, we ensure all studies are performed in AAALAC-accredited and USDA-registered facilities.

  • Oversight: All protocols are reviewed and approved by an Institutional Animal Care and Use Committee (IACUC).

  • 3Rs Principles: We are committed to the principles of Replacement, Reduction, and Refinement in all animal studies.

This commitment ensures the ethical conduct of research and the integrity of the data generated for your regulatory submission.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities